Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro

Hepatocellular carcinoma (HCC) is a leading cause for deaths worldwide. Histone deacetylase (HDAC) inhibition (HDACi) is emerging as a promising therapeutic strategy. However, most pharmacological HDACi unselectively block different HDAC classes and their molecular mechanisms of action are only inco...

Full description

Bibliographic Details
Main Authors: Kim Freese, Tatjana Seitz, Peter Dietrich, Serene M.L. Lee, Wolfgang E. Thasler, Anja Bosserhoff, Claus Hellerbrand
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/11/10/1587
_version_ 1797709794831761408
author Kim Freese
Tatjana Seitz
Peter Dietrich
Serene M.L. Lee
Wolfgang E. Thasler
Anja Bosserhoff
Claus Hellerbrand
author_facet Kim Freese
Tatjana Seitz
Peter Dietrich
Serene M.L. Lee
Wolfgang E. Thasler
Anja Bosserhoff
Claus Hellerbrand
author_sort Kim Freese
collection DOAJ
description Hepatocellular carcinoma (HCC) is a leading cause for deaths worldwide. Histone deacetylase (HDAC) inhibition (HDACi) is emerging as a promising therapeutic strategy. However, most pharmacological HDACi unselectively block different HDAC classes and their molecular mechanisms of action are only incompletely understood. The aim of this study was to systematically analyze expressions of different HDAC classes in HCC cells and tissues and to functionally analyze the effect of the HDACi suberanilohydroxamic acid (SAHA) and trichostatin A (TSA) on the tumorigenicity of HCC cells. The gene expression of all HDAC classes was significantly increased in human HCC cell lines (Hep3B, HepG2, PLC, HuH7) compared to primary human hepatocytes (PHH). The analysis of HCC patient data showed the increased expression of several HDACs in HCC tissues compared to non-tumorous liver. However, there was no unified picture of regulation in three different HCC patient datasets and we observed a strong variation in the gene expression of different HDACs in tumorous as well as non-tumorous liver. Still, there was a strong correlation in the expression of HDAC class IIa (HDAC4, 5, 7, 9) as well as HDAC2 and 8 (class I) and HDAC10 (class IIb) and HDAC11 (class IV) in HCC tissues of individual patients. This might indicate a common mechanism of the regulation of these HDACs in HCC. The Cancer Genome Atlas (TCGA) dataset analysis revealed that HDAC4, HDAC7 and HDAC9 as well as HDAC class I members HDAC1 and HDAC2 is significantly correlated with patient survival. Furthermore, we observed that SAHA and TSA reduced the proliferation, clonogenicity and migratory potential of HCC cells. SAHA but not TSA induced features of senescence in HCC cells. Additionally, HDACi enhanced the efficacy of sorafenib in killing sorafenib-susceptible cells. Moreover, HDACi reestablished sorafenib sensitivity in resistant HCC cells. In summary, HDACs are significantly but differently increased in HCC, which may be exploited to develop more targeted therapeutic approaches. HDACi affect different facets of the tumorigenicity of HCC cells and appears to be a promising therapeutic approach alone or in combination with sorafenib.
first_indexed 2024-03-12T06:42:02Z
format Article
id doaj.art-31bc0b4587964213b514a022a1ccf8c7
institution Directory Open Access Journal
issn 2072-6694
language English
last_indexed 2024-03-12T06:42:02Z
publishDate 2019-10-01
publisher MDPI AG
record_format Article
series Cancers
spelling doaj.art-31bc0b4587964213b514a022a1ccf8c72023-09-03T00:54:49ZengMDPI AGCancers2072-66942019-10-011110158710.3390/cancers11101587cancers11101587Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In VitroKim Freese0Tatjana Seitz1Peter Dietrich2Serene M.L. Lee3Wolfgang E. Thasler4Anja Bosserhoff5Claus Hellerbrand6Institute of Biochemistry (Emil-Fischer Zentrum), Friedrich-Alexander University Erlangen-Nürnberg, Fahrstr. 17, D-91054 Erlangen, GermanyInstitute of Biochemistry (Emil-Fischer Zentrum), Friedrich-Alexander University Erlangen-Nürnberg, Fahrstr. 17, D-91054 Erlangen, GermanyInstitute of Biochemistry (Emil-Fischer Zentrum), Friedrich-Alexander University Erlangen-Nürnberg, Fahrstr. 17, D-91054 Erlangen, GermanyBiobank under the administration of the Human Tissue and Cell Research Foundation. Department of General Visceral- and Transplantation Surgery, Ludwig-Maximilians-University Munich, D-81377 Munich, GermanyHepacult GmbH, Am Klopferspitz 19, D-82152 Planegg/Martinsried, GermanyInstitute of Biochemistry (Emil-Fischer Zentrum), Friedrich-Alexander University Erlangen-Nürnberg, Fahrstr. 17, D-91054 Erlangen, GermanyInstitute of Biochemistry (Emil-Fischer Zentrum), Friedrich-Alexander University Erlangen-Nürnberg, Fahrstr. 17, D-91054 Erlangen, GermanyHepatocellular carcinoma (HCC) is a leading cause for deaths worldwide. Histone deacetylase (HDAC) inhibition (HDACi) is emerging as a promising therapeutic strategy. However, most pharmacological HDACi unselectively block different HDAC classes and their molecular mechanisms of action are only incompletely understood. The aim of this study was to systematically analyze expressions of different HDAC classes in HCC cells and tissues and to functionally analyze the effect of the HDACi suberanilohydroxamic acid (SAHA) and trichostatin A (TSA) on the tumorigenicity of HCC cells. The gene expression of all HDAC classes was significantly increased in human HCC cell lines (Hep3B, HepG2, PLC, HuH7) compared to primary human hepatocytes (PHH). The analysis of HCC patient data showed the increased expression of several HDACs in HCC tissues compared to non-tumorous liver. However, there was no unified picture of regulation in three different HCC patient datasets and we observed a strong variation in the gene expression of different HDACs in tumorous as well as non-tumorous liver. Still, there was a strong correlation in the expression of HDAC class IIa (HDAC4, 5, 7, 9) as well as HDAC2 and 8 (class I) and HDAC10 (class IIb) and HDAC11 (class IV) in HCC tissues of individual patients. This might indicate a common mechanism of the regulation of these HDACs in HCC. The Cancer Genome Atlas (TCGA) dataset analysis revealed that HDAC4, HDAC7 and HDAC9 as well as HDAC class I members HDAC1 and HDAC2 is significantly correlated with patient survival. Furthermore, we observed that SAHA and TSA reduced the proliferation, clonogenicity and migratory potential of HCC cells. SAHA but not TSA induced features of senescence in HCC cells. Additionally, HDACi enhanced the efficacy of sorafenib in killing sorafenib-susceptible cells. Moreover, HDACi reestablished sorafenib sensitivity in resistant HCC cells. In summary, HDACs are significantly but differently increased in HCC, which may be exploited to develop more targeted therapeutic approaches. HDACi affect different facets of the tumorigenicity of HCC cells and appears to be a promising therapeutic approach alone or in combination with sorafenib.https://www.mdpi.com/2072-6694/11/10/1587histone deacetylasehepatocellular carcinomasorafenibhistone deacetylase inhibitor
spellingShingle Kim Freese
Tatjana Seitz
Peter Dietrich
Serene M.L. Lee
Wolfgang E. Thasler
Anja Bosserhoff
Claus Hellerbrand
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
Cancers
histone deacetylase
hepatocellular carcinoma
sorafenib
histone deacetylase inhibitor
title Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
title_full Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
title_fullStr Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
title_full_unstemmed Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
title_short Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
title_sort histone deacetylase expressions in hepatocellular carcinoma and functional effects of histone deacetylase inhibitors on liver cancer cells in vitro
topic histone deacetylase
hepatocellular carcinoma
sorafenib
histone deacetylase inhibitor
url https://www.mdpi.com/2072-6694/11/10/1587
work_keys_str_mv AT kimfreese histonedeacetylaseexpressionsinhepatocellularcarcinomaandfunctionaleffectsofhistonedeacetylaseinhibitorsonlivercancercellsinvitro
AT tatjanaseitz histonedeacetylaseexpressionsinhepatocellularcarcinomaandfunctionaleffectsofhistonedeacetylaseinhibitorsonlivercancercellsinvitro
AT peterdietrich histonedeacetylaseexpressionsinhepatocellularcarcinomaandfunctionaleffectsofhistonedeacetylaseinhibitorsonlivercancercellsinvitro
AT serenemllee histonedeacetylaseexpressionsinhepatocellularcarcinomaandfunctionaleffectsofhistonedeacetylaseinhibitorsonlivercancercellsinvitro
AT wolfgangethasler histonedeacetylaseexpressionsinhepatocellularcarcinomaandfunctionaleffectsofhistonedeacetylaseinhibitorsonlivercancercellsinvitro
AT anjabosserhoff histonedeacetylaseexpressionsinhepatocellularcarcinomaandfunctionaleffectsofhistonedeacetylaseinhibitorsonlivercancercellsinvitro
AT claushellerbrand histonedeacetylaseexpressionsinhepatocellularcarcinomaandfunctionaleffectsofhistonedeacetylaseinhibitorsonlivercancercellsinvitro